Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Change in Acquisitions & Divestments (2016 - 2025)

Rocket Pharmaceuticals' Change in Acquisitions & Divestments history spans 9 years, with the latest figure at $91.0 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments rose 5.22% year-over-year to $91.0 million; the TTM value through Dec 2025 reached $380.8 million, down 0.7%, while the annual FY2025 figure was $380.8 million, 0.7% down from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $91.0 million at Rocket Pharmaceuticals, down from $123.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $123.0 million in Q3 2025 and bottomed at $38.3 million in Q4 2021.
  • The 5-year median for Change in Acquisitions & Divestments is $82.1 million (2022), against an average of $80.9 million.
  • The largest annual shift saw Change in Acquisitions & Divestments surged 247.87% in 2021 before it fell 23.97% in 2023.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $38.3 million in 2021, then surged by 32.7% to $50.8 million in 2022, then surged by 42.35% to $72.3 million in 2023, then increased by 19.54% to $86.5 million in 2024, then grew by 5.22% to $91.0 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Change in Acquisitions & Divestments are $91.0 million (Q4 2025), $123.0 million (Q3 2025), and $84.5 million (Q2 2025).